Introduction
============

Ovarian cancer (OC) is the second most common gynecological malignancy in the United States, accounting for approximately 21,500 new cases of cancer and 14,600 deaths in 2009 ([@b1-mco-0-0-1912]). In Japan, OC is the fourth most common gynecological malignancy with an estimated incidence of nearly 8,000 cases and more than 4,000 deaths every year ([@b2-mco-0-0-1912]). Poor prognostic factors for OC are thought to include the existence of residual tumor tissue and chemotherapy response ([@b3-mco-0-0-1912],[@b4-mco-0-0-1912]). However, such parameters are insufficient for predicting the prognosis of patients with OC. Therefore, a new approach for pre-treatment assessment of OC is pivotal in improving clinical outcomes for OC.

Low skeletal muscle mass (sarcopenia) is useful because it reflects not only a state of degenerative body weight, but also muscle mass wasting in cancer patients. Therefore, sarcopenia is an important physiological change that occurs during the development of cancer cachexia ([@b5-mco-0-0-1912],[@b6-mco-0-0-1912]). Low skeletal muscle mass can be easily investigated using abdominal computed tomography (CT). Cross-sectional CT measurement of the skeletal muscle area (SMA) and psoas area (PA) at the level of the third lumbar vertebra (L3) has been demonstrated to give reliable muscle mass indices for the whole body ([@b7-mco-0-0-1912],[@b8-mco-0-0-1912]). Loss of skeletal muscle mass, which is symptomatic of poor physical condition, is a risk factor for the outcome of various cancer types ([@b9-mco-0-0-1912]--[@b13-mco-0-0-1912]). Volumetric measurements on a three-dimensional (3D) scale are more accurate compared with conventional measurements on a one- or two-dimensional scale ([@b14-mco-0-0-1912],[@b15-mco-0-0-1912]). Multi-detector CT scanning is widely undertaken in routine clinical practice, and 3D constructive CT (3D-CT) can provide volumetric data. This is the first study to investigate whether SMA and PA calculated by CT and psoas major volume (PV) calculated by 3D-CT are associated with clinical parameters and prognosis in patients with OC.

Patients and methods
====================

### Study population

A total of 92 patients with epithelial OC who underwent preoperative assessment at the Department of Obstetrics and Gynecology of Okayama University Hospital between January 2002 and December 2017 were enrolled in this study. The study protocol was approved by the Institutional Review Board of Okayama University Hospital (1704-012). Disease staging was performed according to the International Federation of Gynecology and Obstetrics (FIGO) criteria. All enrolled patients were examined by CT or positron emission tomography-CT (PET-CT) to locate tumor deposits before debulking surgery. Our standard surgical treatment for OC of primary debulking surgery (PDS)/interval debulking surgery (IDS) consists of laparotomy for total abdominal hysterectomy, bilateral salpingo-oophorectomy, and infracolic or total omentectomy to debulk peritoneal tumor masses with maximum effects. All cases of primary debulking surgery (PDS) successfully achieved no residual tumor (R0). Patients with more extensive disease and those unable to undergo surgery started neoadjuvant chemotherapy. Surgical resection was classified as curative (R0) or non-curative (R1 or R2, microscopic or gross residual tumor) in the IDS group. Patients who underwent PDS were treated with or without three to eight cycles of standard chemotherapy. This included three to six cycles of neo-adjuvant chemotherapy with IDS followed by two to five cycles of adjuvant chemotherapy. For standard chemotherapy, we used the TC regimen consisting of paclitaxel (175 mg/m^2^ infused over 3 h) and an area under the curve value of 5 for carboplatin.

### CT imaging analysis

For SMA or PA, a single axial image corresponding to the L3 vertebral body was selected and measured for each CT scan. Cross-sectional CT measurement of the SMA and PA within predefined validated boundaries of −29 to +150 Hounsfield units were measured by software (Synapse Vincent; Fujifilm Medical, Tokyo, Japan). SMA consisting of the abdominal muscles, psoas muscles, and para spinal muscles was demarcated. Selected PA only included the psoas muscle area (right and left). All recipients also underwent 3D-CT. Psoas major volume in the lesion by 3D-CT was measured using image recognition software (Synapse Vincent; Fujifilm Medical, Tokyo, Japan).

### Laboratory data collection

All subjects had their serum albumin, C-reactive protein (CRP) and CA125 levels measured within 1 week prior to treatment. Levels of serum albumin and CRP were measured using latex nephelometry (LT Auto Wako, Osaka, Japan). Serum CA125 levels were measured by electrochemiluminescence immunoassay on the Roche/Hitachi Modular Analysis E170 (Roche Diagnostics, Tokyo, Japan). Briefly, the high Glasgow prognostic score (GPS) group included patients with GPS 2: CRP levels \>1.0 mg/dl and hypoalbuminemia (\<3.5 g/dl). The low GPS group included patients with only one of these factors showing abnormal levels (GPS 1) or none of these abnormalities (GPS 0).

### Statistical analysis

Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Statistical analyses were performed using the Kruskal-Wallis test for comparisons with controls. Spearman correlation analysis was performed between PA and SMA, PV and PA, PV and SMA metric values, which we used to report the correlation and P-values. PFS and OS of the groups were analyzed using the Kaplan-Meier method. Differences between the recurrence and survival curves were examined using the log-rank test. We performed univariate and multivariate analyses using Cox\'s proportional hazards model to determine which factors predict PFS and OS after adjusting for the effects of known prognostic factors. P\<0.05 was considered statistically significant.

Results
=======

Of 285 patients who attended our institutions for treatment of OC during the study period, 92 were found to be eligible following exclusion of ineligible patients after completion of the study measurements by CT and 3D-CT ([Fig. 1](#f1-mco-0-0-1912){ref-type="fig"}). The patients were aged from 15 to 78 years (mean, 55.3 years). FIGO stage, histology, lymph node metastasis, no residual tumor (R0), ascites, neo-adjuvant chemotherapy, GPS, and CA125 are shown in [Table I](#tI-mco-0-0-1912){ref-type="table"}.

With respect to body composition, the median (range) pre-treatment SMA, PA, and PV were 92.92 (range, 47.41--128.91) cm^2^, 9.96 (range, 5.07--18.05) cm^2^, and 195.6 (range, 83.89--351.49) cm^3^, respectively. Inter-measurement correlations of SMA, PA, and PV were analyzed with data from CT scans. The correlations between SMA and PA, PV and PA, and PV and SMA were 0.629, 0.616, and 0.614, respectively ([Fig. 2B](#f2-mco-0-0-1912){ref-type="fig"}).

We examined the correlations between pre-treatment GPS and body composition such as SMA, PA, and PV with OC. The pre-treatment GPSs were as follows: GPS 0, 38 patients (41.3%); GPS 1, 30 (32.6%); and GPS 2, 24 (26.1%). Interestingly, PV was significantly associated with GPS (P=0.010, respectively; [Fig. 2C](#f2-mco-0-0-1912){ref-type="fig"}).

We next investigated whether SMA, PA, and PV are associated with clinical parameters in patients with OC. We found that PA was significantly associated with stage (P\<0.001), histology (P=0.017), lymph node metastasis (P=0.01), ascites (P=0.048), neo-adjuvant chemotherapy (P=0.007), and GPS (P=0.012). Furthermore, PV was significantly associated with age (P=0.019), stage (P\<0.001), histology (P=0.001), lymph node metastasis (P=0.005), ascites (P=0.024), neo-adjuvant chemotherapy (P\<0.001), and GPS (P=0.002; [Table II](#tII-mco-0-0-1912){ref-type="table"}).

Patients underwent follow-up examinations approximately every 1--2 months for the first 6 months, every 3 months for the next 2 years, and every 6 months thereafter. The median PFS and OS times for all patients who were alive at the time of last follow-up were 19.0 and 32.0 months, respectively (range for follow-up periods was 1 to 144 months for both PFS and OS). At the last follow-up point, 44 patients were without evidence of disease (47.8%), 32 patients had died of disease (34.8%), and 16 patients had recurrence and were currently alive with the disease (17.4%).

The PFS and OS of the 92 patients with epithelial OC are shown in [Fig. 3](#f3-mco-0-0-1912){ref-type="fig"}. The cut-off values for SMA, PA, and PV, based on the median values, were 92.92 cm^2^, 9.96 cm^2^, and 195.6 cm^3^, respectively. Kaplan-Mayer curves showed that patients with lower PV had poorer PFS and OS than patients with significantly higher PV (P=0.018 and P=0.006, respectively). Moreover, patients with low SMA had significantly worse OS than those with higher SMA (P=0.030, respectively). Interestingly, PV was superior to SMA and PA in prognosis prediction ([Fig. 3](#f3-mco-0-0-1912){ref-type="fig"}).

The correlations between clinical factors and PFS or OS were assessed in univariate and multivariate analyses ([Table III](#tIII-mco-0-0-1912){ref-type="table"}). In a univariate analysis of PFS and OS, GPS (P\<0.001), age (P=0.001), PV (P=0.021), neo-adjuvant chemotherapy (P\<0.001), stage (P\<0.001), histology (P\<0.001), lymph node metastasis (P\<0.001), no residual tumor (P=0.001), and ascites (P\<0.001) were significantly associated with PFS, whereas GPS (P\<0.001), age (P=0.005), SMA (P=0.035), PV (P=0.009), neo-adjuvant chemotherapy (P=0.003), stage (P\<0.001), lymph node metastasis (P\<0.001), no residual tumor (P\<0.001), and ascites (P=0.008) were significantly associated with OS. In a multivariate analysis, GPS (P=0.048 and P=0.008) and stage (P\<0.001 and P=0.008) were significantly associated with PFS and OS. However, the multivariate analysis showed that PV was not an independent predictor of recurrence and survival in patients with OC.

Discussion
==========

Poor prognostic factors for OC are thought to include the existence of residual tumor tissue and chemotherapy response ([@b3-mco-0-0-1912],[@b4-mco-0-0-1912]). Sarcopenia is an important prognostic risk factor for the outcome of various cancer types. This study aimed to evaluate whether pre-treatment SMA and PA measurements by cross-sectional CT and PV by 3D-CT, which predicts poor prognosis for patients with OC, are associated with recurrence or survival.

Sarcopenia, often observed in patients with cancer, is usually regarded as a marker of malnutrition, cachexia, progressive weight loss, fatigue, and anorexia. It is associated with the loss of body composition of patients with cancer because it causes a reduction in SMA. The relationship between poor prognosis and progressive atrophy of SMA has been reported in various cancer types ([@b16-mco-0-0-1912]--[@b18-mco-0-0-1912]). Muscle tissue areas can be objectively measured using standard abdominal CT. Areas of SMA and PA can also be accurately estimated using this approach. A low SMA area has been associated with poor outcome in various types of cancer ([@b5-mco-0-0-1912]).

Inflammatory markers such as malnutrition and cachexia are important prognostic factors for survival in various cancer types. CRP and albumin have prominent roles in tumor inflammation ([@b19-mco-0-0-1912]--[@b21-mco-0-0-1912]). Inflammation-based prognostic scores, including the GPS, which is a combination of CRP and albumin parameters, is associated with survival in various cancers, including ovarian, lung, and colorectal cancers ([@b22-mco-0-0-1912]--[@b24-mco-0-0-1912]). Furthermore, McSorley *et al* clarified that low radiation attenuation in muscle was correlated with GPS in colorectal cancer ([@b25-mco-0-0-1912]). However, there are no reports of an association between GPS and skeletal muscle mass in OC.

Multi-detector CT scanning is widely accessed in routine practice, and 3D-CT enables volumetric data to be obtained. Volumetric measurements on a 3D scale are more accurate compared with conventional measurements on a one- or two-dimensional scale ([@b14-mco-0-0-1912],[@b15-mco-0-0-1912]). We examined body composition using either cross-sectional CT measurement or 3D-CT measurement. In fact, because only one slice was examined for SMA and PA on a CT sagittal view, it was hard to confirm that it was precisely evaluated ([@b20-mco-0-0-1912]). To our knowledge, this is the first study to evaluate SMA, PA, and PV and the possible prognostic roles of these values in the evaluation of OC.

With respect to body composition, the median pre-treatment SMA, PA, and PV were 92.92 cm^2^, 9.96 cm^2^, and 195.6 cm^3^, respectively. We investigated the association between pre-treatment GPS and body composition such as SMA, PA, and PV with OC. Therefore, PV was more related to pre-treatment GPS than SMI and PA.

We examined whether SMA, PA, and PV were correlated with clinical parameters, using CT for the first two factors and 3D-CT for the latter. We found that PA was significantly associated with stage, histology, lymph node metastasis, ascites, neo-adjuvant chemotherapy, and GPS. Furthermore, PV was significantly associated with age, stage, histology, lymph node metastasis, ascites, neo-adjuvant chemotherapy, and GPS. Our analyses revealed that patients with low PV had significantly poorer PFS and OS than patients with high PV. Interestingly, PV was found to be superior to SMA and PA in prognosis prediction. Univariate analysis showed that high PV was significantly associated with PFS and OS in our study population. However, the multivariate analysis showed that PV was not an independent predictor of recurrence and survival in patients with OC.

This study has some limitations. For example, the number of analyzed samples was small and was obtained from a retrospective cohort in a single hospital. Thus, further confirmation in a prospective trial would help to validate our findings.

In conclusion, this report shows that PV could be a potential imaging biomarker to predict poor prognosis in patients with OC. Based on these results, further sarcopenia research is required to predict prognosis.
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![Study cohort selection flow chart. Flow chart indicated the selection of the study cohort. CT, computed tomography.](mco-11-04-0376-g00){#f1-mco-0-0-1912}

![Sarcopenia images, regression analysis and associations with ovarian cancer. (A) Patient with sarcopenia. Pre-treatment SMA (102.71 cm^2^), PA (10.73 cm^2^) and PV (191.0 cm^3^) measured according to attenuation thresholds of −29 to +150 Hounsfield units. (B) Regression analysis for PA and SMA, SMA and PV, and PV and PA for 92 patients with ovarian cancer. (C) Associations of GPS and SMA, PA, and PV with ovarian cancer. SMA, skeletal muscle area; PA, psoas area; PV, psoas major volume; GPS, Glasgow prognostic score.](mco-11-04-0376-g01){#f2-mco-0-0-1912}

![Kaplan-Meier curves. Kaplan-Meier curves for PFS and OS rates of 92 patients with ovarian cancer according to their pre-treatment SMA, PA and PV. PFS, progression-free survival; OS, overall survival; SMA, skeletal muscle area; PA, psoas area; PV, psoas major volume.](mco-11-04-0376-g02){#f3-mco-0-0-1912}

###### 

Patient and tumor characteristics

  Baseline characteristics           
  ----------------------------- ---- ------
  Stage                              
    I                           32   34.8
    II                          6    6.5
    III                         34   37
    IV                          20   21.7
  Histology                          
    Serous carcinoma            39   42.4
    Clear cell carcinoma        8    8.7
    Mucinous carcinoma          12   13
    Endometrioid carcinoma      11   12
    Other carcinoma             22   23.9
  Lymph node metastasis              
    Absent                      60   65.2
    Present                     32   34.8
  Macroscopic tumor free (R0)        
    Absent                      7    7.6
    Present                     85   92.4
  Ascites                            
    Absent                      76   82.6
    Present                     16   17.4
  Neo-adjuvant chemotherapy          
    Absent                      61   66.3
    Present                     31   33.7
  GPS                                
    0                           38   41.3
    1                           30   32.6
    2                           24   26.1
  CA125                              
    \<35.0 U/ml                 9    9.8
    ≥35.0 U/ml                  83   90.2

###### 

Associations of SMA, PA, PV with clinical factors on ovarian cancer.

                                Numbers   SMA           P-value   PA           P-value                                                 PV             P-value
  ----------------------------- --------- ------------- --------- ------------ ------------------------------------------------------- -------------- -------------------------------------------------------
  Age                                                   0.31                   0.06                                                                   0.019^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^
    \<70 years                  81        94.34±15.82             10.34±2.84                                                           204.82±57.85   
    ≥70 years                   11        89.19±14.90             8.61±2.76                                                            161.77±38.14   
  BMI                                                   0.497                  0.182                                                                  0.498
    \<24.9                      71        92.91±16.37             9.78±2.71                                                            194.9±56.44    
    ≥25.0                       21        95.57±13.17             10.73±3.29                                                           204.82±66.02   
  Stage                                                 0.05                   \<0.001^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^                  \<0.001^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^
    Stage I, II                 39        97.94±16.93             12.32±2.88                                                           237.48±54.62   
    Stage III, IV               53        91.56±13.89             9.41±2.57                                                            180.83±50.90   
  Histology                                             0.236                  0.017^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^                    0.001^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^
    Serous adenocarinoma        39        96.44±17.76             11.06±2.92                                                           219.91±61.14   
    Non-serous carcinoma        53        92.46±12.61             9.63±2.71                                                            182.88±50.30   
  Lymph node metastasis                                 0.187                  0.01^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^                     0.005^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^
    Absent                      62        95.24±15.74             10.98±2.81                                                           213.27±59.07   
    Present                     30        90.7±15.36              9.38±2.72                                                            178.74±46.73   
  Macroscopic tumor free (R0)                           1                      0.085                                                                  0.325
    Absent                      7         92.92±11.63             11.74±2.79                                                           177.52±48.62   
    Present                     85        92.92±16.26             9.78±2.87                                                            197.92±59.51   
  Ascites                                               0.983                  0.048^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^                    0.024^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^
    Absent                      76        92.98±17.12             10.7±2.84                                                            205.66±57.73   
    Present                     16        92.92±8.35              9.14±2.80                                                            169.65±53.99   
  Neo-adjuvant chemotherapy                             0.06                   0.007^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^                    \<0.001^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^
    Absent                      61        95.57±17.72             11.1±2.99                                                            220.47±61.37   
    Present                     31        89.84±11.03             9.41±2.39                                                            180.83±40.65   
  GPS                                                   0.315                  0.012^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^                    0.002^[a](#tfn1-mco-0-0-1912){ref-type="table-fn"}^
    0+1                         68        94.91±15.98             11.08±2.95                                                           218±58.89      
    2                           24        91.15±14.83             9.38±2.39                                                            176.91±43.49   
  CA125                                                 0.998                  0.155                                                                  0.066
    \<35.0 U/ml                 9         92.91±19.27             11.22±2.70                                                           233.13±77.05   
    ≥35.0 U/ml                  83        92.92±15.64             9.78±2.88                                                            194.9±56.58    

P\<0.05; SMA, skeletal muscle area; PA, psoas area; PV, psoas major volume.

###### 

Prognostic factors for progression-free survival and overall survival with ovarian cancer selected by Cox\'s univariate and multivariate analysis.

                                Univariate analysis   Multivariate analysis                                                                                   
  ----------------------------- --------------------- ----------------------- ------------------------------------------------------- ------- --------------- -------------------------------------------------------
  Progression-free survival                                                                                                                                   
    GPS 2                       5.246                 2.909--9.460            \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   2.034   1.006--4.115    0.048^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^
    CA125 (≥35.0 U/ml)          3.99                  0.967--16.461           0.056                                                           --              
    Age (≥70 years)             3.235                 1.606--6.516            0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     1.673   0.740--3.780    0.216
    BMI (≥25.0)                 0.805                 0.411--1.576            0.527                                                           --              
    SMA(\<92.92 cm^2^)          1.272                 0.725--2.230            0.402                                                           --              
    PA (\<9.96 cm^2^)           1.51                  0.854--2.670            0.156                                                           --              
    PV (\<195.6 cm^3^)          1.998                 1.109--3.601            0.021^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     0.818   0.404--1.654    0.576
    Neo-adjuvant chemotherapy   3.778                 2.113--6756             \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   1.162   0.580--2.326    0.672
    Stage (Stage III--IV)       11.099                4.636--26.572           \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   8.065   2.620--24.826   \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^
    Histology (Serous Ca)       2.824                 1.587--5.024            \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   0.979   0.490--1.958    0.952
    Lymph node metastasis       3.309                 1.876--5.834            \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   0.85    0.423--1.707    0.648
    No residual tumor (R0)      4.24                  1.826--9.845            0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     1.92    0.761--4.842    0.167
    Ascites                     3.424                 1.836--6.386            \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   0.979   0.476--2.011    0.953
  Overall survival                                                                                                                                            
    GPS 2                       6.978                 3.336--14.596           \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   3.37    1.381--8.223    0.008^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^
    CA125 (≥35.0 U/ml)          2.654                 0.632--11.149           0.183                                                           --              
    Age (≥70 years)             3.076                 1.410--6.706            0.005^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     1.209   0.459--3.186    0.702
    BMI (≥25.0)                 0.848                 0.382--1.882            0.685                                                           --              
    SMA (\<92.92 cm^2^)         2.186                 1.057--4.518            0.035^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     2.106   0.765--5.802    0.15
    PA (\<9.96 cm^2^)           1.734                 0.851--3.532            0.13                                                            --              
    PV (\<195.6 cm^3^)          2.882                 1.296--6.406            0.009^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     0.981   0.368--2.617    0.969
    Neo-adjuvant chemotherapy   2.937                 1.455--5.929            0.003^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     0.709   0.307--1.638    0.42
    Stage (stage III--IV)       9.956                 3.499--28.659           \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   5.896   1.586--21.923   0.008^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^
    Histology (Serous Ca)       1.812                 0.912--3.600            0.09                                                            --              
    Lymph node metastasis       3.843                 1.917--7.703            \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   0.922   0.400--2.125    0.849
    No residual tumor (R0)      5.611                 2.197--14.335           \<0.001^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^   2.85    0.917--8.851    0.07
    Ascites                     2.902                 1.323--6.367            0.008^[a](#tfn2-mco-0-0-1912){ref-type="table-fn"}^     0.905   0.358--2.286    0.833

P\<0.05; SMA, skeletal muscle area; PA, Psoas area; PV, psoas major volume.
